Safety information

Indications and clinical use:

Victoza® is indicated for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with:

  • Metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.

  • Metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.

  • Metformin and a basal insulin, when diet and exercise plus dual therapy with Victoza® and metformin do not achieve adequate glycemic control.

Victoza® is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.

Not a substitute for insulin. Should not be used in type 1 diabetes.
Victoza® is not indicated for use in pediatric patients.


  • Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

  • Pregnant or breastfeeding women

Most serious warnings and precautions:

Risk of thyroid C-cell tumours: In both genders of rats and mice, liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumours. Patients should be counselled regarding the risk and symptoms of thyroid tumours.

Other relevant warnings and precautions:

  • Cardiovascular effects: Increased heart rate, PR interval prolongation, decreased blood pressure

  • Should not be used for treatment of diabetic ketoacidosis

  • Should not be administered intravenously or intramuscularly

  • Hypoglycemia in combination with a sulfonylurea or insulin

  • Pen for individual use only

  • Pancreatitis

  • Recent myocardial infarction, stroke, and congestive heart failure

  • Hepatic and renal impairment

  • Gastrointestinal disease and adverse reactions

  • Hypersensitivity

  • Thyroid disease and adverse reactions

  • Acute gallbladder disease

For more information:

Please consult the product monograph at for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this advertisement.

The product monograph is also available by calling us at 1-800-465-4334.

Ask Med Info

If you have a specific question about Victoza®, please email our Medical Information team using the form below. We will get back to you as soon as possible.


The latest Victoza® Product Monograph dated November 17, 20171.

The new Victoza® VIP program is a resource for you to use with your patients during consultations, including how-to videos and other resources to get them started.

TRUST in our real-world experience.

#1 GLP-1 receptor agonist dispensed, Canada and worldwide2,3

>1,120,000 patients worldwide have been prescribed Victoza® 3